{"entity":{"id":"nct05862272","kind":"trial","name":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","aka":[],"tldr":"A phase 3 trial of Relugolix in endometrial cancer, run by Sumitomo Pharma Switzerland GmbH, now recruiting.","summary":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis is a phase 3 interventional study registered as NCT05862272 by Sumitomo Pharma Switzerland GmbH, with 1000 participants planned, started 2023-08-14 and due to reach its primary completion in 2029-07. Interventions recorded: Relugolix Combination Tablet.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05862272","url":"https://clinicaltrials.gov/study/NCT05862272"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["relugolix"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05862272","phase":"3","setting":"A Phase 3B, Single-Arm, Open-Label Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids or Moderate to Severe Pain Associated With Endometriosis","sponsor":"Sumitomo Pharma Switzerland GmbH","enrolled":1000,"outcomes":[]},"route":"/trials/nct05862272/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/"}]}}